Inovio Pharmaceuticals (INO) Tax Provisions (2015 - 2019)

Inovio Pharmaceuticals (INO) posted Tax Provisions of -$87764.0 for Q4 2019, up 17.8% sequentially from -$106771.0 in Q2 2019.

Inovio Pharmaceuticals (INO) Tax Provisions (2015 - 2019) Analysis & Trends

Inovio Pharmaceuticals has reported Tax Provisions for 3 years, with the latest figure at -$87764.0 in Q4 2019.

Quarterly Tax Provisions changed N/A year-over-year to -$87764.0 in Q4 2019, while the trailing twelve-month figure through Sep 2020 was -$87764.0 (up 48.24% YoY) and the FY2019 annual result came in at -$257335.0, down 111.86% from the prior year.
Tax Provisions rose to -$87764.0 in Q4 2019 per INO's latest filing, from -$106771.0 in the prior quarter.
Over five years, Tax Provisions peaked at $2.2 million in Q1 2018 and troughed at -$1.8 million in Q3 2015.
A 3-year average of -$30881.7 and a median of -$97267.5 in 2019 frame the typical range for Tax Provisions.
The widest YoY moves for Tax Provisions: up 102.89% in 2019, down 102.89% in 2019.
Over 3 years, Tax Provisions stood at -$308520.0 in 2015, then surged by 803.3% to $2.2 million in 2018, then plunged by 104.04% to -$87764.0 in 2019.
According to Business Quant data, Tax Provisions over the past three periods registered -$87764.0, -$106771.0, and -$62800.0 for Q4 2019, Q2 2019, and Q1 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	59.00 Mn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	15.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	75.45 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.31 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	1.90 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-90.33 Mn
10	Inovio Pharmaceuticals	97.94 Mn	97.94 Mn	-	-

Download Data